IceCure Medical Ltd (ICCM)

Market Cap	66.07M
Revenue (ttm)	2.79M
Net Income (ttm)	-15.58M
Shares Out	78.65M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,365,916
Open	0.8300
Previous Close	0.8200
Day's Range	0.7000 - 0.8400
52-Week Range	0.4800 - 1.6600
Beta	2.35
Analysts	Strong Buy
Price Target	2.50 (+197.62%)
Earnings Date	Aug 13, 2025

About ICCM

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense s...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCM
• Website: https://www.icecure-medical.com

Financial Performance

In 2024, IceCure Medical's revenue was $3.29 million, an increase of 1.92% compared to the previous year's $3.23 million. Losses were -$15.32 million, 4.55% more than in 2023.

Analyst Forecast

According to one analyst, the rating for ICCM stock is "Strong Buy" and the 12-month stock price target is $2.5.

Price Target

$2.5

(197.62% upside)

Analyst Consensus: Strong Buy